Best Diversified Pharmaceuticals Companies in China
The 109 best Diversified Pharmaceuticals companies in China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: CStone Pharma.
China's Diversified Pharmaceuticals sector is bigger than most people realize, and this directory ranks the 109 companies we track by disclosed equity funding and recent momentum. Total disclosed capital sits at $2.4B across the cohort, with CStone Pharma leading at $410M, followed by Mabwell at $278M and Abbisko Therapeutics at $263M. No unicorns yet, which tells you something about where valuation cycles are in this market right now.
The macro backdrop is hard to ignore. The global diversified pharmaceuticals market was valued at roughly $2,050B in 2023 and is forecast to reach $3,206B by 2033, a CAGR of around 6.95%, driven by chronic disease prevalence, rising urban healthcare access, and sustained government expenditure. China fits squarely into those demand drivers. Hot coverage themes this quarter include generic drug approval pipelines and drug distribution efficiency, and if you look at the investor roster here, names like Hillhouse, Qiming Venture Partners, and Lilly Asia Ventures signal that institutional conviction in the space is real and active. So the question isn't whether China's pharma build-out continues. It's which companies in this directory capture the next funding cycle.
- The Business Research Company
Ranked: Best Diversified Pharmaceuticals companies in China
| # | Company | Disclosed funding | Last round | Stage | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CStone Pharma Developing and licensing novel drugs for diseases including cancer and autoimmune diseases | $410M | 68 mo ago | Public | 476 | 2016 | — | — | 1 partnership |
| 2 | Mabwell R & D company focused on manufacturing of pharmaceutical products for multiple therapeutic products | $278M | 73 mo ago | Public | 1,451 | 2017 | Datao Liu Co-Founder | — | — |
| 3 | Abbisko Therapeutics Developing novel small molecule drugs for immunomodulatory pathways to treat cancer | $263M | 65 mo ago | Public | 252 | 2016 | — | 309 patents Small-molecule kinase inhibitor drugs targeting FGFR4, CSF‑1R, CDK, CD73, PARP for cancer therapy | — |
| 4 | Genor Biopharma Developer of biosimilar monoclonal antibodies for treating multiple diseases | $216M | 72 mo ago | Public | 222 | 2007 | — | 45 patents Bispecific/trispecific immune‑checkpoint antibodies for cancer immunotherapy | — |
| 5 | Shandong Xuanzhu Pharmaceutical Technology Developer of therapies for treating cardiovascular diseases, cancer, and diabetes | $210M | 53 mo ago | Series B | — | 2002 | Haigui CEO | — | — |
| 6 | Allist Pharmaceutical Technology Developer of small molecules for cancer and diabetic treatment | $171M | 85 mo ago | Series A | 870 | 2004 | — | — | — |
| 7 | Shandong Freda Pharmaceutical Group R&D company manufacturing drugs for multiple therapeutic areas | $116M | 54 mo ago | Series D | — | 1991 | Ling Peixue Founder | — | — |
| 8 | Xbiome Developer of an AI-enabled bioinformatics platform for the discovery of drugs using intestinal microbiome 64AI top 20%Funding top 36%Moat top 38%Market top 49% All 5 signals ▾AItop 20% Fundingtop 36% Moattop 38% Markettop 49% Globalbottom 36% AI: Classified as an AI company Funding: Raised $108M across 2 rounds · 2 rounds over 8 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $108M | 53 mo ago | Series B | 63 | 2017 | — | — | — |
| 9 | Kira Pharmaceuticals R&D company focused on manufacturing of drugs for multiple therapeutic areas | $100M | 65 mo ago | Series B | 39 | 2017 | Gonghua Pan Co-Founder | 28 patents Therapeutic antibodies targeting complement proteins C2 and C5a for immune modulation | — |
| 10 | Advaccine Biotech Developer of preventive and therapeutic vaccines | $70M | 62 mo ago | Series B | 191 | 2016 | Jane YU CEO | — | — |
| 11 | Trinomab Developer of immunotherapeutics for multiple diseases | $69M | 61 mo ago | Series A | 48 | 2015 | Zheng Weihong CEO | — | — |
| 12 | Excalipoint Biotechnology company developing next-generation T-cell engager platforms for cancer and autoimmune diseases | $69M | 3 mo ago | Seed | — | 2025 | Jielun Zhu Co-Founder & CFO & CBO | — | — |
| 13 | Suzhou Ze Jing Biological Pharmaceutical Company developing small molecules & eukaryotic cell based recombinant protein drugs | $62M | 101 mo ago | Series B | 843 | 2009 | — | — | — |
| 14 | Guangzhou Yinming Biomedical Technology R&D company focused on manufacturing of drugs for multiple therapeutic areas | $60M | 57 mo ago | Series A | 230 | 2019 | — | — | — |
| 15 | ACCRO R&D company focused on manufacturing of drugs for multiple therapeutic areas | $50M | 53 mo ago | Series B | — | 2017 | Sudan He Co-Founder | — | — |
| 16 | Suzhou Kaituo Pharmaceutical Company developing drugs for cancer, arthritis & CVS diseases | $44M | 101 mo ago | Public | 290 | 2009 | Tong Youzhi CEO & President | — | — |
| 17 | Mab venture Early stage company developing therapeutic antibodies | $35M | 99 mo ago | Deadpooled | — | 2013 | George Wang CEO & Founder | 5 patents Therapeutic antibodies targeting LAG-3 immune checkpoint for cancer immunotherapy | — |
| 18 | Zezheng Pharmaceutical R&D company manufacturing drugs for multiple therapeutic areas | $31M | 53 mo ago | Series B | — | 2021 | He Dunwei CEO | — | — |
| 19 | Shankang Medical R&D based manufacturer of drugs for multiple therapeutics | $28M | 57 mo ago | Series B | 127 | 2017 | — | — | — |
| 20 | Zhejiang Shimai Pharmaceutical Manufacturer of drugs for multiple therapeutic areas | $22M | 53 mo ago | Series C | — | 2017 | Weizao Chen CEO | — | — |
| 21 | West Lake R&D company focused on manufacturing of drugs for multiple diseases | $15M | 59 mo ago | Series A | — | 2019 | Gao Xiaofei Founder | — | — |
| 22 | Uni-Bio Science Chinese bio-similar and bio-betters company | $15M | 107 mo ago | Public | 340 | 2001 | — | — | — |
| 23 | Ruiwen Information Technology R&D company focused on manufacturing of drugs for multiple therapeutic areas | $2M | 97 mo ago | Seed | — | 2015 | Michelle Li Co-Founder | — | — |
Top 12 Diversified Pharmaceuticals companies in China
#1
Seed · Shanghai, Shanghai · founded 2025$68.7Mraised▾
Biotechnology company developing next-generation T-cell engager platforms for cancer and autoimmune diseases. The company aims to overcome tumor challenges in immunology and oncology.
- Mar 2026Seed$68.7M
#2
Public · Shanghai, Shanghai · founded 2016 · 476 employees$410Mraised▾
CStone Pharma, a Shanghai-Suzhou startup, is developing and licensing novel drugs with a focus on immuno-oncology along with drugs for cardiovascular diseases, hematology and autoimmune diseases (e.g - rheumatoid arthritis). It has a robust oncology pipeline with eight assets in clinical stages. It is working on various targets including IDHm1, PDL-1, FGFR4, RET, PD-1, etc. The lead molecule, TIBSOVO has got FDA approval.
- Sep 2020Post IPO$200M
- May 2018Series B$260M
- Jul 2016Series A$150M
#3
Series B · Jinan, Shandong · founded 2002$209.7Mraised▾
Shandong Xuanzhu Pharmaceutical Technology is a subsidiary of Sihuan Pharmaceutical Holdings. They are developing therapies for treating cardiovascular diseases, cancer, and diabetes. Their lead candidate XZP - 5491 is used to treat cancer. It is an ERBB 2 (epidermal growth factor receptor) receptor, antagonist. Other candidates are mostly in phase I clinical trials. They also offer development services for APIs and intermediates such as process development, scale-up, synthesis, etc.
- Dec 2021Series B$94.1M
- Aug 2020Series A$115.5M
#4
Public · Shanghai, Shanghai · founded 2016 · 252 employees$263Mraised▾
Abbisko therapeutics is developing novel small molecule drugs for immunomodulatory pathways to treat cancer. The company's pipeline has three preclinical candidates. The exact mechanism of action of each moleule has not been disclosed but the company is possibly advancing a STING/TLR activator, IDO/CSF1R inhibitor and TGF agonist. The company's integrated R&D center locates in the Shanghai Zhangjiang Hi-Tech Park. The company claims to be surrounded by numerous top CRO, CMO and clinical contract organizations in the area, with whom they collaborate o research in drug discovery and development. In the future, the company aims to target other diseases such as liver disease, viral infections and mental disease
- Jan 2021Series D$123M
- Mar 2020Series C$70M
- Mar 2019Series B$42M
- Feb 2017Series A$28M
#5
Public · Pudong, Shanghai · founded 2017 · 1451 employees$278.1Mraised▾
R & D company focused on manufacturing of pharmaceutical products for multiple therapeutic products
- Apr 2020Series A$278.1M
- Nov 2019Seed—
#6
Public · Shanghai, Shanghai · founded 2007 · 222 employees$215.9Mraised▾
Genor Biopharma is a developer of biosimilar monoclonal antibodies for treating multiple diseases. It has developed therapeutic monoclonal antibodies (mAbs), Fc-fusion proteins and recombinant therapeutic proteins. Its lead candidate, a trastuzumab biosimilar is in a multi-center clinical trial & the second candidate, an infliximab biosimilar helps in treating cancer.
- Jun 2020Series B$160M
- Jun 2018Series A$55.9M
#7
Series B · Shenzhen, Guangdong Province · founded 2017 · 63 employees$107.5Mraised▾
Developer of an AI-enabled bioinformatics platform for the discovery of drugs using intestinal microbiome. The company uses Fecal microbiota transplantation (FMT) technology for the development of drugs for multiple diseases. It includes extraction of microbiota from the stool of healthy people through various methods and then transplant it into patients and used to treat various diseases.
- Dec 2021Series B$100M
- Dec 2020Series B—
- Nov 2019Series B—
- Jun 2019Series A—
#8
Series D · Jinan, Shandong · founded 1991$115.9Mraised▾
R&D company manufacturing drugs for multiple therapeutic areas
- Dec 2021Series D$115.9M
#9
Series B · Hong Kong, Hong Kong · founded 2017 · 39 employees$99.5Mraised▾
R&D company focused on manufacturing of drugs for multiple therapeutic areas
- Jan 2021Series B$53.5M
- Nov 2020Series B$46M
#10
Series A · Shanghai, Shanghai · founded 2004 · 870 employees$171Mraised▾
Shanghai Ailisi Pharmaceutical Technology is developing antitumor and antidiabetic products. Its lead candidate AST2818 is an EGFR inhibitor is in preclinical trials and being developed for non-small cell lung cancers. Also developing PPAR, TGF and FGFR inhibitors and nanoliposomal drug delivery systems for cancer treatment. Its anti-diabetic portfolio includes SGLT2 and DPP IV inhibitors.
- May 2019Series A$171M
#11
Series B · Beijing, Beijing · founded 2016 · 191 employees$70.3Mraised▾
Developer of preventive and therapeutic vaccines
- Mar 2021Series B$66M
- Feb 2020Series A$4.3M
#12
Series B · Suzhou, Jiangsu · founded 2017$50Mraised▾
Developer of small molecule innovative drugs designed for inflammatory, autoimmune diseases and cancer. The company focuses on the molecular mechanism of regulated cell death and the related pathogenesis in human diseases, improving the current therapeutic standard of targeted disease areas.
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Diversified Pharmaceuticals coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.